Fortrea (FTRE) 44th Annual J.P. Morgan Healthcare Conference summary

Company Overview and Strategic Direction

• Spun out from Labcorp in 2023, leveraging over 30 years of experience and a heritage rooted in Covance.

• Operates as a pure-play global CRO with a diversified client base, serving both large pharma and small biotech firms.

• Focuses on modernizing clinical trial delivery through AI, machine learning, automation, predictive analytics, and digital-first initiatives.

• Offers comprehensive services across the clinical trial continuum, including clinical pharmacology, operations, data management, consulting, and Phase I–IV trials.

• Maintains a global workforce of approximately 14,500 employees across 100 countries and expertise in over 20 therapeutic areas.

Market Environment and Industry Trends

• Cautiously optimistic about a return to growth in pharma R&D investments, projecting 3%-4% near-term growth and a 3.5% CAGR through 2030.

• Outsourced clinical development spend is anticipated to grow ~4%, driven by complexity and regulatory demands.

• Oncology leads therapeutic areas, with growth in immunology, endocrinology/metabolism, and neurology.

• Recent headwinds in biotech funding and pharma budgets are subsiding, improving the outlook.

• Outsourcing trends show ebbs and flows between FSP, full-service, and hybrid models, with hybrid solutions gaining traction.

Operational and Commercial Execution

• Emphasizes a framework of reach, relevance, and repeat to drive commercial growth and customer engagement.

• Prioritizes customer intimacy, bespoke solutions, and project management strength.

• Revenue mix in Q3 2025: 57% large pharma, 43% biotech and other segments; top 10 clients represent ~60% of revenue.

• Net Promoter Scores have improved steadily since 2023, reflecting enhanced client satisfaction.

• Strategic partnerships and preferred provider relationships drive consistent revenue and high utilization.